This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2017 by Idera Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Idera Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT02644967
First received: December 23, 2015
Last updated: September 19, 2017
Last verified: September 2017
  Purpose
The goal of this clinical research study is to find the recommended dose of the study drug IMO-2125 that can be given in combination with ipilimumab or in combination with pembrolizumab to patients with metastatic melanoma. Researchers also want to learn if the study drug combination can help to control the disease. The safety of the drug combination will also be studied.

Condition Intervention Phase
Metastatic Melanoma Drug: IMO-2125 Drug: Ipilimumab Drug: Pembrolizumab Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma

Resource links provided by NLM:


Further study details as provided by Idera Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Phase 1: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 to determine the recommended Phase 2 dose of IMO-2125. [ Time Frame: 33 weeks (29 weeks of treatment, 4 weeks follow up ]
  • Phase 2: Number of participants with objective response using irRECIST. [ Time Frame: 33 weeks (29 weeks of treatment, 4 weeks follow up ]

Estimated Enrollment: 100
Study Start Date: December 2015
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
IMO-2125 intratumoral injection plus ipilimumab
Drug: IMO-2125
Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
Drug: Ipilimumab
4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
Other Name: Yervoy®
Experimental: Arm 2
IMO-2125 intratumoral injection plus pembrolizumab
Drug: IMO-2125
Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
Drug: Pembrolizumab
Drug: Pembrolizumab Administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks beginning on Week 2.
Other Name: Keytruda®

Detailed Description:
This is an open-label Phase 1/2 study to determine the recommended dose and assess the safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of IMO-2125 when administered in combination with ipilimumab or pembrolizumab. The study will be conducted in 2 parts; a dose-escalation portion (Phase 1) to evaluate safety and tolerability of multiple dose levels and a Phase 2 portion to assess efficacy.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have histologically confirmed metastatic melanoma with measurable, stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease.
  2. Patients must have symptomatic or radiographic progression during or after treatment with a PD-(L)1 inhibitor administered either as monotherapy or in combination.

    1. The interval between last PD-(L)1 directed treatment and start of study treatment should be at least 21 days.
    2. Prior BRAF or MEK inhibitor treatment is not required. However, for patients with known BRAF status:

      • Those with BRAF wild type may have had a maximum of two previous systemic regimens for the treatment of melanoma.
      • Those with a BRAF mutation may have had a maximum of three previous systemic regimens for the treatment of melanoma.
    3. Prior ipilimumab is permitted.
    4. Previous treatment with either a PD-1 inhibitor (for patients enrolling on the IMO-2125 + pembrolizumab combination) or CTLA-4 inhibitor (for patients enrolling on the IMO-2125 + ipilimumab combination if applicable) should not have been accompanied by DLT for which permanent discontinuation is recommended (per USPI).
  3. Phase 1 patients must have at least two measurable tumor lesions ≥ 1.0 cm that are accessible to biopsy. Phase 2 patients must have at least one measurable lesion (per RECIST v1.1) which may be the same site that is used for the intratumoral injections.
  4. Patients must be ≥ 18 years of age.
  5. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
  6. Patients must meet the following laboratory criteria:

    1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1500/mm3)
    2. Platelet count ≥ 75 x 10^9/L (75,000/mm3)
    3. Hemoglobin ≥ 8.0 g/dL (4.96 mmol/L)
    4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/minute
    5. Aspartate aminotransferase (AST) ≤ 2.5 x ULN; alanine aminotransferase (ALT) ≤ 2.5 x ULN; AST/ALT < 5 x ULN if liver involvement
    6. Serum bilirubin ≤ 1.5 x ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin < 3 mg/dL
  7. Women of childbearing potential (WOCBP) and men must agree to use effective contraceptive methods from Screening throughout the study treatment period and until at least 3 months after the last dose of ipilimumab or at least 4 months after the last dose of pembrolizumab.
  8. Patients must have an anticipated life expectancy > 3 months.

Exclusion Criteria:

  1. Patients who have received prior therapy with a TLR agonist, excluding topical agents. Patients who have received experimental vaccines or other investigational immune therapies should be discussed with the Medical Monitor to confirm eligibility.
  2. Patients who have received systemic treatment with IFN-α within the previous 6 months prior to enrolling into this study.
  3. Patients with known hypersensitivity to any oligodeoxynucleotide.
  4. Patients with active autoimmune disease requiring disease-modifying therapy.
  5. Patients requiring concurrent systemic steroid therapy higher than physiologic dose (7.5 mg/day of prednisone).
  6. Patients with any form of active primary or secondary immunodeficiency.
  7. Patients with another primary malignancy that has not been in remission for at least 3 years.
  8. Patients with active systemic infections requiring antibiotics or active hepatitis A, B, or C.
  9. Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.
  10. Patients who previously had a severe reaction to treatment with a human antibody.
  11. Patients with known central nervous system, meningeal, or epidural disease.
  12. Women who are pregnant or breastfeeding.
  13. Patients with impaired cardiac function or clinically significant cardiac disease.
  14. Patients with ocular melanoma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02644967

Contacts
Contact: Idera Study Monitor 877-888-6550 ext 2 patientinfo@iderapharma.com

Locations
United States, Arizona
The University of Arizona Cancer Center Not yet recruiting
Tucson, Arizona, United States, 85719
Contact: Montaser Shaheen, MD         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Igor Puzanov, MD         
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Douglas B Johnson, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Adi Diab, MD         
United States, Utah
University of Utah- Huntsman Cancer Institute Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Robert Andtbacka, MD         
Sponsors and Collaborators
Idera Pharmaceuticals, Inc.
Investigators
Study Director: Idera Medical Director Idera Pharmaceuticals, Inc.
  More Information

Additional Information:
Responsible Party: Idera Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02644967     History of Changes
Other Study ID Numbers: 2125-204
Study First Received: December 23, 2015
Last Updated: September 19, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Pembrolizumab
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 21, 2017